Biotech IV Monitor

ACAD — ACADIA Pharmaceuticals Inc.

$4.3B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for ACADIA Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.

Next readoutAugust 2027in ~9 months
Upcoming readouts53 Phase 3
Market cap$4.3B
Cash & investments$976Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-04

Upcoming readouts

Phase 2 ACP-211
Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant · NCT07284667
August 2027
Recruiting
Phase 2/3 ACP-204
Alzheimer's Disease Psychosis · NCT06159673
January 2028
Recruiting
Phase 2 ACP-204
Lewy Body Dementia Psychosis · NCT07029581
February 2028
Recruiting
Phase 3 ACP-204
Lewy Body Dementia Psychosis · NCT07095465
February 2029
Recruiting
Phase 3 ACP-204
Alzheimer's Disease Psychosis · NCT06194799
April 2029
Enrolling

Cash position

ACADIA Pharmaceuticals Inc. reported $976M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $54M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow ACAD, you can start the conversation.
Track ACAD in real time
See live implied volatility for ACAD and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ACAD
Contact — questions or corrections about ACAD: dukeupt@gmail.com